Altered hepatic disposition of anionic drugs secondary to drug interactions, chemical exposure, disease states or genetic predisposition has important therapeutic implications. Systemic exposure, and therefore the magnitude and duration of pharmacologic response, may be affected substantially by changes in hepatic translocation of drugs. Likewise, perturbations in hepatic transport can influence systemic, intestinal and, perhaps most importantly, hepatic toxicity. The long-term objective of this ongoing research program is to develop a mechanistic understanding of how alterations in hepatic transport influence overall hepatobiliary disposition of anionic drugs and derived metabolites. A multiexperimental approach incorporating relevant in vitro expression systems (Sf9 cells, Xenopus laevis oocytes); a novel sandwich-cultured (SC) primary hepatocyte model that retains hepatic transport mechanisms, provides quantitative data on biliary and basolateral excretion, and is amenable to transporter knockdown by RNAi; isolated perfused livers using TR- rats, a model of Mrp2 deficiency; and an in vivo human study will be employed to elucidate mechanisms and consequences of altered hepatic transport of model anionic substrates. The hypothesis that multiple Mrp isoforms contribute to basolateral excretion of anionic drugs and metabolites from the liver will be tested, proteins that contribute significantly to this process will be identified, and kinetics of transport will be determined for model substrates. Purportedly """"""""specific"""""""" inhibitors of hepatic canalicular transport may interact with basolateral transport proteins, resulting in a previously unrecognized category of drug-drug interactions. The ability of these inhibitors to modulate basolateral excretion, and the consequences of such modulation on hepatobiliary disposition, will be explored. The hypothesis that hepatic response mechanisms (basolateral exporters, other canalicular transporters, and hepatic Phase II enzymes) compensate for impaired Mrp2 function will be evaluated; the role of nuclear hormone receptors in these compensatory responses, and the kinetic consequences of such compensation, will be defined. Finally, the ability of human SC hepatocytes to predict hepatobiliary disposition of a model anion in humans will be assessed with a novel clinical protocol that allows quantitation of biliary excretion in healthy humans. Elucidating mechanisms of hepatic transport, and identifying functional consequences of alterations in these processes, is an important step in understanding the multiplicity of factors that determine systemic exposure (and ultimately biologic response) to xenobiotics, and is prerequisite to exploiting these processes to achieve desirable therapeutic outcomes. ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Research Project (R01)
Project #
5R01GM041935-16
Application #
7251494
Study Section
Xenobiotic and Nutrient Disposition and Action Study Section (XNDA)
Program Officer
Okita, Richard T
Project Start
1991-04-01
Project End
2009-06-30
Budget Start
2007-07-01
Budget End
2008-06-30
Support Year
16
Fiscal Year
2007
Total Cost
$308,798
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Pharmacology
Type
Schools of Pharmacy
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Kaullen, Josh D; Owen, Joel S; Brouwer, Kim L R et al. (2018) Pharmacokinetic/Pharmacodynamic Model of CW002, an Investigational Intermediate Neuromuscular Blocking Agent, in Healthy Volunteers. Anesthesiology 128:1107-1116
Kenna, J Gerry; Taskar, Kunal S; Battista, Christina et al. (2018) Can Bile Salt Export Pump Inhibition Testing in Drug Discovery and Development Reduce Liver Injury Risk? An International Transporter Consortium Perspective. Clin Pharmacol Ther 104:916-932
Guo, Yingying; Chu, Xiaoyan; Parrott, Neil J et al. (2018) Advancing Predictions of Tissue and Intracellular Drug Concentrations Using In Vitro, Imaging and Physiologically Based Pharmacokinetic Modeling Approaches. Clin Pharmacol Ther 104:865-889
Brock, William J; Beaudoin, James J; Slizgi, Jason R et al. (2018) Bile Acids as Potential Biomarkers to Assess Liver Impairment in Polycystic Kidney Disease. Int J Toxicol 37:144-154
Thakkar, Nilay; Slizgi, Jason R; Brouwer, Kim L R (2017) Effect of Liver Disease on Hepatic Transporter Expression and Function. J Pharm Sci 106:2282-2294
Ali, Izna; Slizgi, Jason R; Kaullen, Josh D et al. (2017) Transporter-Mediated Alterations in Patients With NASH Increase Systemic and Hepatic Exposure to an OATP and MRP2 Substrate. Clin Pharmacol Ther :
Gonzalez, Daniel; Rao, Gauri G; Bailey, Stacy C et al. (2017) Precision Dosing: Public Health Need, Proposed Framework, and Anticipated Impact. Clin Transl Sci 10:443-454
Watt, Kevin M; Cohen-Wolkowiez, Michael; Williams, Duane C et al. (2017) Antifungal Extraction by the Extracorporeal Membrane Oxygenation Circuit. J Extra Corpor Technol 49:150-159
Oliveira, Cláudia; Joshee, Lucy; George, Hannah et al. (2017) Oral exposure of pregnant rats to toxic doses of methylmercury alters fetal accumulation. Reprod Toxicol 69:265-275
Pierre, V; Johnston, C K; Ferslew, B C et al. (2017) Population Pharmacokinetics of Morphine in Patients With Nonalcoholic Steatohepatitis (NASH) and Healthy Adults. CPT Pharmacometrics Syst Pharmacol 6:331-339

Showing the most recent 10 out of 108 publications